IDH2 and central nervous system cancer: Fourth, IDH mutations prevail in younger brain tumor patients [51], most commonly ages between 20 and 40, with surprising preference to the frontal lobe tumors and associated with less contrast enhancement and less necrosis compared to the non-IDH mutant gliomas [52].